Acquisition - June 3, 2015
SymCel Device Hits Markets
SymCel’s calScreener™ technology is going in nine locations across five different countries in a mixture of university institutions and pharmaceutical companies. The nine include four signings in Sweden, two signings in Switzerland, and one each in Holland, South Africa, Germany and South East Asia Scientific data published in The Biotechnology Journal shows that CalScreener’s isothermal microcalorimetry label free […]
In a new job - June 2, 2015
Recipharm Taps Chief Strategy Officer
Jean-François Hilaire was named to the new position of chief strategy officer for Recipharm on Monday, according to the company. Hilaire began work Monday and will join the Group’s Executive Committee. “Jean-François Hilaire brings valuable and relevant experience in the pharmaceutical industry in general, and also has important insights from the outsourcing of drug development […]
Regulatory compliance - June 2, 2015
BMS Sues Exec Who Goes to AZ
Bristol-Myers Squibb has filed a lawsuit against a former executive for accepting a job with AstraZeneca, alleging he violated a non-compete agreement in the process, according to court documents. The executive, David Berman, who worked for Bristol-Myers for a decade, most recently was the vice president of the company’s immuno-oncology exploratory development team. He was promoted […]
Business article - June 2, 2015
Orphan Drugs Spur M&A Interest
Thanks to the potential for higher prices, limited competition and favorable regulations, orphan drugs continue to be popular to manufacture and also attractive to buy, and Moody’s predicts they will continue to generate merger and acquistion activity. Nearly half of recent acquisitons involved orphan drugs, or medications that treat serious conditions that affect fewer than […]
New Market - June 1, 2015
Isofol Drug Receives US Patent
The use and pharmaceutical composition of Isofol Medical AB’s [6R]-methylene-tetrahydrofolate (Modufolin®), to reduce toxicity resulting from multi-targeting antifolate chemotherapy, has received a patent from the U.S. Patent and Trademark Office. Modufolin® is a folate-based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. Isofol provided evidence demonstrating the […]
Intellectual Property - June 1, 2015
Fungal Nail Drug Gets Patent
An improved formulation of Moberg Pharma’s OTC product for the treatment of fungal nails, sold in the U.S. under the Kerasal Nail® brand, recently received a patent from the European Patent Office, according to Moberg. The patent expires in 2034. The corresponding U.S. patent was also granted earlier this spring and Moberg Pharma is pursuing […]
